A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...
Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...
Generic statins and angiotensin receptor blockers typically used for heart disease also have the potential to bolster the immune systems of patients with Ebola virus and other life-threatening ...
Novo Nordisk said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage ...
Novo Nordisk's experimental drug, CagriSema, shows promise beyond weight loss, potentially offering significant ...
Tenaya Therapeutics said on Friday the U.S. Food and Drug Administration has placed a clinical hold on its trial of an ...
With better access to tools like CCTA and diagnostic tools that leverage CCTA, clinicians can better support their patients in managing overall cardiovascular health, patients will benefit from less ...
People with type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a ...
Common medicines can harm your heart. Cardiologist Dr. Dimitry Yaranov warns about five drug types. Painkillers, chemotherapy ...
The results of a late-stage drug trial released Thursday are raising hopes that type 1 diabetes patients with chronic kidney ...
Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat and cardiovascular risks in MASLD models. The drug duo works better together ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback